Trialbee

Quotes

Trialbee’s solution is highly attractive since it directly targets patients and enables them to engage in clinical studies. E-recruitment follows the trend of patients increasingly seeking disease information online. Trialbee’s recruitment technology solves a large, well known and costly problem within the pharmaceutical industry.

Marianne Pilgaard, Head of Clinical Research, Novo Nordisk Scandinavia.

Novo Nordisk is the market leader within its segment and has a longstanding and broad experience within research and development. Novo Nordisk has a solid pipeline within diabetes and haemophilia and several clinical trials are expected in the coming years. At Trialbee, we are delighted to cooperate with Novo Nordisk, a company in the forefront of communicating with and engaging patients in product development

Tobias Folkesson, CEO, Trialbee.

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

E-health company Trialbee secures a share issue of € 2.4 million ($ 3.3 million)

Thu, Dec 05, 2013 08:00 CET

Trialbee expands the shareholder base by closing a round of investment in a new share issue reaching € 2.4 million. The investment is led by Industrifonden and Briban Invest followed by a group of well-known business angels represented by former TAT founder Hampus Jakobsson.Trialbee has developed a technical platform that enables online patient recruitment for clinical trials. Trialbee facilitates for pharmaceutical companies to recruit the right participants for specific trials fast and reliable, thus shortening time to market for new drugs and treatments. Trialbee will use the proceeds

There are no items matching the current filter

There are no more items matching the current filter

Back to top

Share

Quotes

E-health company Trialbee secures a share issue of € 2.4 million ($ 3.3 million)